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Depression in the Elderly: Diagnostics 
Background 
1. Definition  
o Abnormal emotional state marked by  
 Altered mood that may occur daily  
 Diminished interest or pleasure in most or all activities 
o Symptoms can include  
 Poor appetite, weight loss or gain 
 Insomnia or hypersomnia 
 Feelings of hopelessness or worthlessness, guilt 
 Difficulty concentrating and thinking 
 Recurrent thoughts of death or suicide 
o See DSM-IV criteria 
2. General information  
o Common, treatable, and potentially fatal 
o Distinct from early-onset depression 
o Less personality dysfunction and presence of depressed mood 
o More somatic complaints 
o Cognitive symptoms may be more prominent 
o Pts. usually have medical co-morbidity 
o Treatment  
 Usually effective for community dwellers, inpatients, and nursing-home 
residents 
 Effective/safe in presence of co-morbid illness and dementia 
 Improves outcome measures for pain, overall health, and quality of life 
Pathophysiology 
1. Pathology  
o Mechanism may be similar to depression in younger age groups  
 Neurotransmitters (serotonin, norepinephrine, dopamine) may be involved 
o Vascular disease may predispose or precipitate depression  
2. Incidence/prevalence  
o 17-37% of elderly primary care pts. have depression 
o 15-20% of medically ill pts. have major depression 
o 14% of medically ill pts. have minor depression 
o Subsyndromal depression has prevalence of 13-27% in elderly 
o 37-56% of nursing home dwellers have major, minor, or subsyndromal depression 
o Nursing home settings  
 Cognitively intact residents 10-20% 
 Cognitively impaired 50-70%  
3. Risk factors  
o History of depression 
o Chronic medical illness 
o Female 
o Single or divorced status 
o Social isolation 
o Lower socioeconomic status 
o Uncontrolled pain 
o Insomnia 
o Functional impairment 
o Cognitive impairment 
4. Morbidity/mortality  
o Higher rates of disability and hospitalization 
o Increased caregiver burden 
o Lower rates of medication compliance 
o Decreased functional status and quality of life 
o One-year mortality is 8-15% 
o Death occurs by co-morbid illness or suicide  
 Insufficient evidence to recommend for / against routine screening by 
primary care clinicians to detect suicide risk in general population  
Diagnostics 
1. History  
o Elderly are more likely to demonstrate anhedonia than middle-age adults 
o Elderly less likely to be depressed than middle-age adults 
o Ask about vegetative signs  
 Sleep 
 Concentration 
 Energy level 
 Appetite/weight loss 
o Screen for cognitive impairment (Mini-mental status exam )  
o Memory status  
o Assess suicide risk  
 Directly ask about the frequency and content of suicidal ideation 
 Evaluate the patient's access to means of committing suicide 
2. Physical exam  
o Appearance (may appear unkempt or flat) 
o Speech (may speak slowly) 
o Thought process and content (may be slower with poor concentration) 
o Cognitive evaluation with mental status exam 
3. Diagnostic testing  
o Laboratory  
 TSH, B12, chemistry, CBC, UA  
 To rule out common metabolic causes 
o Geriatric depression scale  
4. Diagnostic criteria  
o DSM-IV criteria for major depression  
 Must have at least 5 of 9 symptoms during the same 2-wk period  
 Depressed mood 
 Sleep disturbance 
 Lack of interest or pleasure in activities 
 Guilt and feelings of worthlessness 
 Lack of energy 
 Loss of concentration and difficulty making decisions 
 Anorexia or weight loss 
 Psychomotor agitation or retardation 
 Suicidal ideation 
 One must be a cardinal symptom (depressed mood or anhedonia) 
 Must involve impairment of functioning 
o Geriatric depression scale  
 Score > 5 (S/S: 88/93) 
o Dysthymia (minor depression)  
 Chronic disturbance of mood of at least 2 years duration, involving either 
depressed mood or loss of interest or pleasure in all or almost all usual 
activities 
o Subsyndromal depression  
 Depressive symptoms that affect well-being and quality of life but do not 
meet criteria for major depression or dysthymia 
Differential Diagnosis 
1. Key DDx  
o Medical illness 
o Medications  
 Pain medications  
 Codeine, propoxyphene 
 Antihypertensives  
 Clonidine, reserpine 
 Hormones  
 Estrogen, progesterone, cortisol, prednisone, anabolic steroids 
 Cardiac medications  
 Digitalis, propranolol 
 Anticancer agents  
 Cycloserine, tamoxifen, vinblastine, vincristine 
 Parkinson's disease agents  
 Levodopa, bromocriptine 
 Arthritis medications  
 Indomethacin 
 Tranquilizers/anti-anxiety drugs  
 Diazepam, triazolam 
o Bipolar disorder 
o Substance abuse (alcohol) 
o Grief reaction 
2. Extensive DDx  
o Hypothyroidism 
o Infections 
o Congestive heart failure 
o Myocardial infarction 
o Dementia 
o Anemia 
o Vitamin deficiencies 
Acute Therapy 
1. Assess risk of suicide  
o Hopelessness 
o General medical illnesses 
o Family history of substance abuse 
o Depression 
o Personal history of substance abuse 
o Male gender 
o Caucasian 
o Psychotic symptoms 
o Living alone 
o Prior suicide attempts 
2. If necessary, hospitalize  
o Psychosis is present 
o Suicidal ideation with a specific plan, severe hopelessness, or significant 
substance abuse 
o Outpatient medication trial is unsafe because of other medical problems 
Pharmacotherapy 
1. Start low, go slow 
2. Both antidepressants and counseling similarly beneficial for mild-to-moderate depression 
 
3. Selective serotonin reuptake inhibitors (SSRIs)  
o Considered first line because of safety and side-effect profile 
o Effective for symptom relief of depression combined with anxiety  
o Potential interactions with  
 Monoamine oxidase inhibitors (MAOIs) 
 Tricyclic antidepressants (TCAs) 
 Neuroleptics 
 Antiarrhythmics 
 Antihistamines 
o Potential side effects  
 GI distress 
 Sexual dysfunction 
 Weight gain 
 Headache 
o Starting and maintenance dosages for SSRIs  
 Sertraline 25 mg qD (usual dose: 50-100 mg) 
 Paroxetine 5 mg qD (usual dose: 20-50 mg) 
 Citalopram 10-20 mg qD (usual dose: 20-60 mg) 
 Fluoxetine 5 mg qD (usual dose: 20-80 mg) 
 Fluvoxamine 25 mg qHS (usual dose: 50-300 mg) 
o If pt unresponsive to SSRIs  
 Optimize dose/duration of therapy before switching  
 At least 8 weeks of treatment before SSRI is deemed inadequate 
 Only 23% of patients who have not responded to 8 weeks of fluoxetine 
respond to a still longer course of fluoxetine 
o When initiating antidepressant tx for patients who have not been treated for 
depression previously, sertraline and escitalopram have shown to be superior to 
other "new-generation" antidepressants  
o STAR*D trial  
 Randomized study 
 Assigned patients who did not benefit from citalopram to 1 of 3 other 
drugs 
 Sustained-release bupropion 
 Sertraline 
 Extended-release venlafaxine 
 1 in 4 patients achieved remission after switching to antidepressant from 
another drug class 
 Further switches in antidepressant monotherapy had low success rate (10-
20%) 
 Mixed evidence supports combining different antidepressants  
 There is cohort study combining citalopram and bupropion  
 More effective than switching to alternate antidepressant 
 Other cohort studies did not find significant difference 
between switching and augmenting 
 An arm of the STAR*D trial added either sustained- release bupropion or 
buspirone to the failed citalopram therapy  
 30% of patients with depression unresponsive to citalopram had 
remission when bupropion-SR or buspirone was added 
 STAR*D reports do not compare the 2 strategies of switching or 
combining drugs directly 
4. Serotonin Norepinephrine Reuptake Inhibitors (SNRIs)  
o Desvenlafaxine 50 mg qD (max dose 400 mg/day)  
 Adverse drug reactions shown for 50 mg/d dose  
 Higher than placebo 
 >10% include diarrhea, dizziness 
o Duloxetine 40-60 mg/d PO qD/BID; NMT 60 mg/d  
 Adverse drug reactions >10% include  
 Constipation (11%) 
 Dry mouth (15%) 
 Insomnia (11%) 
 Abnormal orgasm (3%) 
 Anorexia (8%) 
o Venlafaxine 25-50 mg BID (usual dose 75-375 mg)  
 Consider in treatment- resistant depression 
 Side effects  
 Anxiety 
 Sexual dysfunction 
 Increased blood pressure 
 Mild sedation 
5. TCAs  
o Equally effective as SSRIs 
o Potential interactions with antiarrhythmics, MAOIs 
o Potential side effects  
 Anticholinergic effects 
 Sedation 
 Orthostatic hypotension 
 Weight gain 
 Cardiac effects 
 Lower seizure thresholds 
o Measurement of blood levels is recommended to monitor therapy  
o Obtain a baseline electrocardiogram 
o Preferred TCAs (ie, lower anticholinergic profile)  
 Desipramine: 10-25 mg qHS (usual dose: 25-300 mg) 
 Nortriptyline: 10-25 mg qHS (usual dose: 25-250 mg) 
6. Atypical SSRIs  
o First line  
 Bupropion: 50 mg BID (usual dose: 100-450 mg)  
 May be as effective as SSRIs and TCAs 
 Potential interactions with MAOIs 
 Side effects include lower seizure threshold 
o Second line  
 Mirtazapine: 15 mg qHS (usual dose: 15-45 mg)  
 Side effects: sedation, increased appetite, constipation, asthenia 
7. MAOIs  
o Infrequently used  
o Side effects: hypertension, hypotension 
o Food-drug interactions 
8. Other agents  
o Lithium  
 Can produce clinical improvement when added to ineffective 
antidepressant tx  
o Triiodothyronine (T3)  
 Supplementation at <50 mcg/day increases effectiveness of antidepressant 
tx  
9. Avoid sedatives/hypnotics such as benzodiazepines  
o Lack of efficacy in treating depression 
o Risks/side effects: abuse potential, increased falls  
Psychotherapy  
1. As effective in geriatric population as in middle-age adults 
2. Both antidepressants and counseling are similarly beneficial for mild- moderate 
depression  
3. Older adults have better treatment compliance 
4. Psychotherapy addresses issues that are unlikely to be affected by medications  
o Grief 
o Transitions 
o Family conflicts 
Electroconvulsive Therapy (ECT)  
1. Indications  
o For severe drug-resistant depression 
o Associated psychotic features that are resistant to pharmacotherapy 
o Severe catatonia 
2. Contraindications  
o Recent myocardial infarction 
o Brain tumor 
o Cerebral aneurysm 
o Uncontrolled congestive heart failure 
3. Effectiveness  
o Evidence of short-term efficacy 
o High relapse rate over 6-12 mo 
4. Adverse effects  
o Post-ECT transient confusion 
o Risk of cardiovascular events 
o Mortality rate: 0.01% 
Follow-Up 
1. Return to office  
o Follow up at 1-2 wk intervals until stable 
o Adjust dose every 2-6 wk as needed 
o Continue treatment for 6-12 mo 
o Monitor closely for relapse 
2. Refer to specialist  
o Refer to geropsychiatry if treatment is ineffective 
3. Admit to hospital  
o Concerns for pt. safety (suicide risk) 
o Severe depression 
o Severe drug-resistant depression 
o Associated psychotic features that are resistant to pharmacotherapy 
o Severe catatonia 
Prognosis 
1. 54-84% of elderly respond completely to treatment 
2. 12-24% of pts. relapse with recurrence rates >40% at 2 years 
3. Treatment  
o Effective for community dwellers, inpatients, and nursing-home residents 
o Effective and safe in the presence of co-morbid illness and dementia 
o Improves outcome measures in pain, overall health, and quality of life 
4. One-year mortality rate is 8-15%  
o Death occurs by co-morbid illness or suicide 
Prevention 
1. Effective prevention is difficult 
2. Helpful measures  
o Social interaction such as support groups that deal with losses and changes 
o Staying in contact with family, friends, and neighbors 
o Participating in absorbing activities 
o Volunteering to help others 
o Learning a new skill, such as computer technology, cooking, or gardening 
o Sharing humorous stories 
o Maintaining a healthy diet 
o Exercise 
3. Screening  
o Screening for depression recommended  
 Only when staff- assisted depression care supports are in place to assure 
accurate diagnosis, effective treatment, and follow up 
o USPSTF recommends against routinely screening adults for depression when 
staff- assisted depression care supports are not in place  
 There may be considerations that support screening for depression in an 
individual patient 
o USPSTF concludes that evidence is insufficient to recommend for or against 
routine screening by primary care clinicians to detect suicide risk in the general 
population 
Patient Education 
1. http://familydoctor.org/online/famdocen/home/seniors/mental-health/588.html 
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